Swipe or use the arrows to view product images.
99% Raw Finished Powder Peptide Tz/Reta for Weight Loss 10mg 15mg 30mg Vial Manufacture Supply G-Lp1 Peptides Tz/Nad for Fat Dissovling Once-Weekly Reta Mt2 Nmn
| Price | $10.00 |
|---|---|
| Min Order | 10 vial |
| Availability | In Stock |
| Shipping From | Jiangsu, China |
| Popularity | 610 people viewed |
Model NO.:
N/A
CAS No.:
N/a
Formula:
N/a
EINECS:
N/a
Type:
Peptides Powder
Appearance:
Powder
Quality:
Top Quality
Colour:
White
Name:
N/a
Mf:
N/a
MW:
N/a
CAS:
N/a
Packing:
1kg/Foil Bag or 25kgs/Drum
Usage:
for Research Use Only
Trademark:
RDG
Transport Package:
as Customer's Requirement
Specification:
5mg/vial; 10mg/vial; 15mg/vial; 30mg/vial
Origin:
China
Product Description
99% Raw Finished Powder Peptide Tz/Reta for Weight Loss 10mg 15mg 30mg Vial Manufacture Supply G-Lp1 Peptides Tz/Nad for Fat Dissovling Once-Weekly Reta Mt2 NMN
Application:
Novel weight loss peptides (Rta,Smag-TIDE,TZ,Cagrin,CagrinS)were approved wellness for weight loss. They are newest
class of chemical products better known for its ability to improve blood sugar control.
Obesity is a complex disease that occurs when an individual's weight is higher than what is considered healthy for his/her height.
According to the CDC, people with a body mass index (BMI) between 25 and 29.9 are considered overweight, and people with a
BMI of 30 or higher are considered obese.
Weight Loss peptides works in the treatment of obesity by targeting three different hunger regulating hormones:
1.GIP (gastric inhibitory peptide or glucose-dependent insulinotropic polypeptide) is an incretin hormone that is released from the
gut after eating. It stimulates the beta-cells in the pancreas to secrete.
2.G-LP-1r (glucagon-like peptide-1r) is also an incretin hormone that stimulates the beta-cells to secrete.
- glucagon is a hormone secreted from the alpha-cells in the pancreas. It stimulates glucose production in the liver and helps
maintain adequate plasma glucose concentrations.
The peptide has been nicknamed 'triple G' because it is an agonist of all three receptors.
Phase 2 clinical trial results published in The New England Journal of Medicine show weight loss peptides achieved up to 17.5%
mean weight reduction at 24 weeks in adults with obesity and overweight. In a secondary endpoint, retatrutide demonstrated a
mean weight reduction up to 24.2% at 48 weeks.
Weight loss pepides as an injection that are administered once-weekly.
In the research items,they showed glucose control and weight loss, type 2 diabetes mellitus (T2DM).
| Product name | Tz |
| Appearance | White powder |
| Purity | 99% |
| Storage | Keep in a cool, dry, dark location in a tightly sealed container or cylinder. |
| Shelf Life | 24 Months |
Application:
Novel weight loss peptides (Rta,Smag-TIDE,TZ,Cagrin,CagrinS)were approved wellness for weight loss. They are newest
class of chemical products better known for its ability to improve blood sugar control.
Obesity is a complex disease that occurs when an individual's weight is higher than what is considered healthy for his/her height.
According to the CDC, people with a body mass index (BMI) between 25 and 29.9 are considered overweight, and people with a
BMI of 30 or higher are considered obese.
Weight Loss peptides works in the treatment of obesity by targeting three different hunger regulating hormones:
1.GIP (gastric inhibitory peptide or glucose-dependent insulinotropic polypeptide) is an incretin hormone that is released from the
gut after eating. It stimulates the beta-cells in the pancreas to secrete.
2.G-LP-1r (glucagon-like peptide-1r) is also an incretin hormone that stimulates the beta-cells to secrete.
- glucagon is a hormone secreted from the alpha-cells in the pancreas. It stimulates glucose production in the liver and helps
maintain adequate plasma glucose concentrations.
The peptide has been nicknamed 'triple G' because it is an agonist of all three receptors.
Phase 2 clinical trial results published in The New England Journal of Medicine show weight loss peptides achieved up to 17.5%
mean weight reduction at 24 weeks in adults with obesity and overweight. In a secondary endpoint, retatrutide demonstrated a
mean weight reduction up to 24.2% at 48 weeks.
Weight loss pepides as an injection that are administered once-weekly.
In the research items,they showed glucose control and weight loss, type 2 diabetes mellitus (T2DM).
They can be just used for the research purpose.
Normally, They will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details,
please refer to the manual:Handling and Storage of Synthetic Peptides.
Benifits:
Semg&Cagris are a single agonist peptide ,Semg&Cagris can be used for the research of obesity treatment or cravings
suppression,T2dm Therapies,and so on.
Tz&Cagris are a Dual agonists peptide ,Tz&Cagris can be used for the research of Anti-obesity or appetite Suppression and so
on.
Rta is a triple agonist peptide ,Rta can be used for the research of Anti-obesity,burn fat,boost energy.
Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details,
please refer to the manual:Handling and Storage of Synthetic Peptides.
What is Rta?
Rta is a synthetic peptide, known for its unique action as a triple receptor agonist. This peptide, also referred to by its code name
LY-3437943, targets three key receptors: glucagon-like peptide-1 (G-LP-1r,GIP),and glucagon (GCG). Each of these receptors
plays an important role in regulating metabolism, with a particular focus on weight Loss,energy expenditure, and blood glucose
levels.
The compound is designed to activate these three receptors simultaneously, with special emphasis on GIP, to help manage
metabolic conditions like type 2 diabetes and support weight loss. Retatrutide is composed of 39 amino acids and is structurally
engineered to maintain stability and prolonged activity in the body. This design makes it an attractive candidate for improving
metabolic health and supporting weight management.
Rta's mode of action is what sets it apart from other peptides. Its ability to address multiple aspects of metabolic regulation could
offer significant benefits for individuals seeking to manage their weight or improve glycemic control.
Important details for researchers:
1.Synthetic design: Though primarily targeting GIP receptors, retatrutide has been designed to also activate G-LP-1r and GCG
receptors, enhancing its effects in regulating metabolism and supporting weight management.
receptors, enhancing its effects in regulating metabolism and supporting weight management.
2.Extended activity: The peptide includes a fatty acid component that enhances stability, allowing for less frequent dosing,
typically once a week.
typically once a week.
3.Clinical trials: Retatrutide is being evaluated in Phase-3 clinical trials, primarily for its effectiveness in supporting weight loss,
with positive results in improving glycemic control and reducing body weight.
with positive results in improving glycemic control and reducing body weight.
3.Regulatory status: Currently, the peptide is available for research purposes, though it has not yet been approved by regulatory
bodies such as the FDA.
bodies such as the FDA.
For Research Purpose Only. Purchasing objects are required to be companies and labs, not for personal use.
- Similar Products
$3000.00
1 Ton (MOQ)
2-Hydroxyethyl Acrylate of CAS No: 818-61-1
Qingdao Salus International Trade Co., Ltd.